Tandem Diabetes Care Inc. Common Stock (NASDAQ: TNDM)
39 Days left to seek lead plaintiff status.
The Complaint alleges that during the Class Period, Defendants disseminated materially false and misleading statements and/or concealed material adverse facts about the Company, causing Plaintiff and other shareholders to purchase Tandem’s securities at artificially inflated prices. On November 2, in an investment call and Form 8-K filing, the Company revised its 2022 forecast downward to the range of $800 to $805 million. Reasons stated for the scale back included increased competition in the diabetes care sector, complications due to the COVID pandemic, and macroeconomic factors such as inflation.